Inovio Pharmaceuticals Inc (NASDAQ: INO) stock suffered a major decline of -10.9% on 9/3/24. The shares closed at $6.43. Trading volume in this decline was normal. The stock has been exceptionally strong relative to the market over the last nine months but has declined -14.4% during the last week.
Current PriceTarget Research Rating
INO’s future returns on capital are forecasted to be in line with the cost of capital. Accordingly, the company is expected to continue to be Value Creation neutral.
Inovio Pharmaceuticals has a current Value Trend Rating of C (Neutral). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing very contradictory signals. Inovio Pharmaceuticals has a very low Appreciation Score of 12 but a very high Power Rating of 88, and the Neutral Value Trend Rating results.
Rating Review
In light of this highly negative price change we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment